Fusion Net Receivables from 2010 to 2026

FSPM Stock  USD 0.0001  0.00  0.00%   
Fusion Pharm Net Receivables yearly trend continues to be very stable with very little volatility. Net Receivables is likely to drop to 359.10. During the period from 2010 to 2026, Fusion Pharm Net Receivables quarterly data regression pattern had sample variance of 93.3 M and median of  420.00. View All Fundamentals
 
Net Receivables  
First Reported
2010-12-31
Previous Quarter
378
Current Value
359.1
Quarterly Volatility
9.7 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Fusion Pharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fusion Pharm's main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 164 K, as well as many indicators such as . Fusion financial statements analysis is a perfect complement when working with Fusion Pharm Valuation or Volatility modules.
  
Build AI portfolio with Fusion Stock
Check out the analysis of Fusion Pharm Correlation against competitors.
To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.
Evaluating Fusion Pharm's Net Receivables across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Fusion Pharm's fundamental strength.

Latest Fusion Pharm's Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Fusion Pharm over the last few years. It is Fusion Pharm's Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fusion Pharm's overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Fusion Net Receivables Regression Statistics

Arithmetic Mean3,812
Geometric Mean611.63
Coefficient Of Variation253.45
Mean Deviation6,039
Median420.00
Standard Deviation9,661
Sample Variance93.3M
Range29.4K
R-Value(0.56)
Mean Square Error68.7M
R-Squared0.31
Significance0.02
Slope(1,065)
Total Sum of Squares1.5B

Fusion Net Receivables History

2026 359.1
2025 378.0
2013 420.0
2012 66.0

About Fusion Pharm Financial Statements

Fusion Pharm investors utilize fundamental indicators, such as Net Receivables, to predict how Fusion Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Receivables 378.00  359.10 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Fusion Pharm is a strong investment it is important to analyze Fusion Pharm's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fusion Pharm's future performance. For an informed investment choice regarding Fusion Stock, refer to the following important reports:
Check out the analysis of Fusion Pharm Correlation against competitors.
To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Will Consumer Staples Distribution & Retail sector continue expanding? Could Fusion diversify its offerings? Factors like these will boost the valuation of Fusion Pharm. Market participants price Fusion higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fusion Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.15)
Revenue Per Share
0.133
Return On Assets
(1.38)
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fusion Pharm's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.